JP2023537369A - ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法 - Google Patents

ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法 Download PDF

Info

Publication number
JP2023537369A
JP2023537369A JP2023508084A JP2023508084A JP2023537369A JP 2023537369 A JP2023537369 A JP 2023537369A JP 2023508084 A JP2023508084 A JP 2023508084A JP 2023508084 A JP2023508084 A JP 2023508084A JP 2023537369 A JP2023537369 A JP 2023537369A
Authority
JP
Japan
Prior art keywords
ketotifen
nsaid
administered
subject
cov
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023508084A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023537369A5 (https=
Inventor
ジャクリーン エム． アイバーセン
トーマス エー． ダール
Original Assignee
セン－ジャム ファーマシューティカル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セン－ジャム ファーマシューティカル エルエルシー filed Critical セン－ジャム ファーマシューティカル エルエルシー
Publication of JP2023537369A publication Critical patent/JP2023537369A/ja
Publication of JP2023537369A5 publication Critical patent/JP2023537369A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023508084A 2020-08-06 2021-08-06 ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法 Pending JP2023537369A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063062138P 2020-08-06 2020-08-06
US63/062,138 2020-08-06
PCT/US2021/044897 WO2022032069A1 (en) 2020-08-06 2021-08-06 Compositions and methods for treating or preventing disease associated with beta coronavirus infection

Publications (2)

Publication Number Publication Date
JP2023537369A true JP2023537369A (ja) 2023-08-31
JP2023537369A5 JP2023537369A5 (https=) 2024-08-14

Family

ID=80117684

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023508084A Pending JP2023537369A (ja) 2020-08-06 2021-08-06 ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法

Country Status (10)

Country Link
US (1) US20240033259A1 (https=)
EP (1) EP4192457B1 (https=)
JP (1) JP2023537369A (https=)
KR (1) KR20230048517A (https=)
CN (1) CN116322662A (https=)
AU (1) AU2021321535A1 (https=)
CA (1) CA3188387A1 (https=)
IL (1) IL300406A (https=)
MX (1) MX2023001570A (https=)
WO (1) WO2022032069A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046201A1 (en) 2017-08-30 2019-03-07 SEN-JAM Pharmaceutical LLC METHODS AND COMPOSITIONS FOR INHIBITING ADVERSE REACTIONS ASSOCIATED WITH VACCINATION
CN116178373B (zh) * 2022-12-06 2024-06-18 南方科技大学 非甾体抗炎药和gs-441524的二联体化合物及其制备方法与用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
US20190060297A1 (en) * 2017-08-30 2019-02-28 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Adverse Effects Associated with Vaccinations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
US20190060297A1 (en) * 2017-08-30 2019-02-28 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Adverse Effects Associated with Vaccinations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOMENI, ROBERTO ET AL.: ""Model based approach for estimating the dosage regimen of indomethacin a potential antiviral treat", JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, vol. 47, no. 3, JPN6025040375, 20 May 2020 (2020-05-20), pages 189 - 198, ISSN: 0005697428 *
JIMNEZ-ALBERTO, ALICIA ET AL.: ""Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors"", COMPUTATIONAL BIOLOGY AND CHEMISTRY, vol. 88, JPN6025040376, 25 June 2020 (2020-06-25), pages 107325, ISSN: 0005697429 *
MARINELLA, MARK A.: ""Indomethacin and resveratrol as potential treatment adjuncts for SARS‐CoV‐2/COVID‐19"", INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, vol. 74, no. 9, JPN6025040374, 12 June 2020 (2020-06-12), ISSN: 0005697427 *
NAPOLI, PIETRO EMANUELE ET AL.: ""A Panel of Broad-Spectrum Antivirals in Topical Ophthalmic Medications from the Drug Repurposing A", JOURNAL OF CLINICAL MEDICINE, vol. 9, no. 8, JPN6025040377, 30 July 2020 (2020-07-30), pages 2441, ISSN: 0005697430 *

Also Published As

Publication number Publication date
EP4192457A1 (en) 2023-06-14
AU2021321535A1 (en) 2023-03-23
IL300406A (en) 2023-04-01
EP4192457A4 (en) 2024-09-18
MX2023001570A (es) 2023-05-03
CN116322662A (zh) 2023-06-23
WO2022032069A1 (en) 2022-02-10
CA3188387A1 (en) 2022-02-10
KR20230048517A (ko) 2023-04-11
EP4192457B1 (en) 2026-03-25
US20240033259A1 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
US20200323843A1 (en) Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus
CN102065897B (zh) 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
JP6567781B2 (ja) ウイルス感染症の治療用チアゾリド化合物
CN117695284A (zh) 冠状病毒感染的治疗
JP2023537369A (ja) ベータコロナウイルス感染症に関連する疾患を治療または予防するための組成物及び方法
US10765630B2 (en) Methods and compositions to treat enteropathic arthritis
US20240115559A1 (en) Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
JP2023502355A (ja) Ｓ１ｐ１受容体に関連する状態を処置する方法
JP2023531872A (ja) 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法
CN117396505A (zh) 治疗炎症的方法
US20240189305A1 (en) Therapeutic agent for coronavirus infection
JP2025504519A (ja) Ｓａｒｓ－ｃｏｖ－２に起因する感染症の予防および／または処置における使用のための化合物
JP2025523818A (ja) 慢性移植片対宿主疾患の治療のためのベルモスジルの投与方法
CN115397404A (zh) 用于治疗covid-19的cxcl8抑制剂
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227